Welcome to CNUS CCCME| 中文版

Home>News Content

(item164-178)Highlighted Foreign Cooperation Projects of Shandong Province-Pharmaceuticals and Biotechnology Industry

Soruce:中美省州合作专题子站 Author:中美省州合作专题子站 Add Time:2014-08-01 00:00:00

 No. 164 Heze Enzyme Degradation Preparing Low Molecular Heparin Industrial Production Project

I. Project name

Heze Enzyme Degradation Preparing Low Molecular Heparin Industrial Production Project

II. Brief introduction of project unit

Shandong Shenlian Biologic Technology Co., Ltd. is located in Yuncheng County Industrial Park, and mainly produces green food and biologic and medical intermediate products such as casing, heparin sodium and low molecular heparin sodium. It is one of the largest direct production suppliers of casing and heparin sodium industry in China. The company now has 300 employees, including 102 high and middle technicians, total assets of RMB 220 million, liability rate of 36% and bank credit level of AA+. In January-November 2013, it realized output value of RMB 110 million, profit and tax of RMB 20.12 million and exporting amount of USD 15 million.

III. Project contents and construction capacity

The project uses “fusion heparinase and heparinase to produce low molecular heparin technology”, and builds factory building and equipment required by 400 billion unit/year low molecular heparin sodium project.

IV. Project construction conditions

Low molecular heparin sodium is new generation of heparin type anti-thrombotic drug developed in recent ten years. Heparin has strong anticoagulant effect, is the first first selective drug for preventing thromboembolic disease caused by deep vein thrombosis, etc, and has several biologic effects such as anti-inflammatory, antiallergic, antivirus and anticancer.

V. Total project investment

USD 20 million

VI. Analysis and prediction of market and economic benefits

After the project is put into production completely, it can realize annual sales income of RMB 410 million, exporting amount of USD 25 million, total investment profit rate of 15.2%, financial internal rate of return of 16.8% and static payback period (including construction period) of 6.8 years.

VII. Cooperation form

Solely foreign funded, joint venture, cooperative operation.

VIII. Contact information

Address: Heze Commercial Bureau

Contact: Tian Zhongtian

Postcode: 274000

Telephone: +86-530-6220275

Email: 5336400@163.com


No. 165 Heze 80 Million Set/year Drug (Drug Foil) Packing Project

I. Project name

Heze 80 Million Set/year Drug (Drug Foil) Packing Project

II. Brief introduction of project unit

Heze Wanxing Drug Packing Co., Ltd, is located in Yuncheng County Industrial Park, and has registered capital of RMB 30 million. The product uses various particles and sheets such as high density polyethylene (HDPE) and polypropylene (PP) as raw materials, and use new technologies such as blow molding, injection molding, blow and injection two-step method, injection blow molding and compression molding to manufacture drug packing. At present, it has 150 employees, including 56 high and middle technicians, and has total assets of RMB 50 million, liability ratio of 46% and bank credit level of AA. In January-November 2013, it realized output value of RMB 65 million, profit and tax of RMB 10.2 million.

III. Project contents and construction capacity

The project purchases 2 new drug packing material production lines, and builds 80 million set/year drug (drug foil) packing production line and relevant facilities.

IV. Project construction conditions

The company obtains a batch of know-hows and patent technologies. With continuous development and innovation of technology, drug packing forms change continuously, polyethylene bottle, polypropylene bottle, polymer bottle, aluminum plastic packing, strip packing and strip complex film will become popular types of solid form drug packing.

V. Total project investment

USD 25 million

VI. Analysis and prediction of market and economic benefits

After the project is put into production completely, it can realize annual sales income of RMB 1 billion, profit and tax of 120 million, investment payback period of 4.8 years, investment profit rate of 25.78% and static payback period of 5.1 years.

VII. Cooperation form

Solely foreign funded, joint venture.

VIII. Contact information

Address: Heze Commercial Bureau

Contact: Tian Zhongtian

Postcode: 274000

Telephone: +86-530-6220275

Email: 5336400@163.com


No. 166 Heze Dicloxacillin Sodium, Flucloxacillin Sodium and Tazobactam Sodium Production Project

I. Project name

Heze Dicloxacillin Sodium, Flucloxacillin Sodium and Tazobactam Sodium Production Project

II. Brief introduction of project unit

Shandong Bairui Pharmaceutical Co., Ltd. is production base of APIs of semi-synthetic antibiotics, which integrates research, development, pilot-scale experiment, production and trade. It mainly produces oxacillin sodium, cloxacillin sodium, sulbactam sodium, azlocillin sodium, mezlocillin sodium and amoxicillin sodium, and has annual semi-synthetic penicillin raw medicine of 150 tons.

III. Project contents and construction capacity

According to the needs of foreign and domestic markets, developed products such as oxacillin sodium, cloxacillin sodium, sulbactam sodium, azlocillin sodium, mezlocillin sodium and amoxicillin sodium form scale product, and obtain good economic benefit, and various products such as ticarcillin sodium and amitriptyline sodium can’t form scale temporarily due to limit of production capacity.

IV. Project construction conditions

The company owns core production technologies of semi-synthetic antibiotics. It obtains drug approval numbers of 8 sterile APIs, and all products pass national GMP authentication. The products use solvent crystallization, and have good crystal shape, high purity and low emission.

V. Total project investment

USD 35 million

VI. Analysis and prediction of market and economic benefits

After project reaches its design capacity, it can realize annual business income of RMB 480 million and total profit of RMB 65 million.

VII. Cooperation form

Joint venture, cooperative operation.

VIII. Contact information

Address: Heze Commercial Bureau

Contact: Tian Zhongtian

Postcode: 274000

Telephone: +86-530-6220275

Email: 5336400@163.com


No. 167 Jining Yulong Drug Park Chemical Drug Project

I. Project name

Jining Yulong Drug Park Chemical Drug Project

II. Brief introduction of project unit

Shandong Kongfu Pharmaceutical Co., Ltd. is under Shandong Yulong Mine Group, is a modern traditional Chinese medicine pharmaceutical enterprise, and has total assets of RMB 80 million.

III. Project contents and construction capacity

1. Project contents: It is planning to introduce funds and new chemical drugs, and to build chemical drug industrial base. 2. Construction capacity: The project has floor area of 400 mu.

IV. Project construction conditions

The production line passes national drug GMP authentication, uses traditional Chinese medicine as leading, and owns 7 dosage forms and 35 types, i.e., oral liquid, syrups, granule, tablet, capsule, pill and powder.

V. Total project investment

USD 130 million

VI. Analysis and prediction of market and economic benefits

After the project is put into production completely, it can realize annual new sales income of USD 160 million and profit of USD 50 million.

VII. Cooperation form

Joint venture, solely foreign funded, cooperative operation.

VIII. Contact information

Address: Qufu Commercial Bureau, Shandong Province

Contact: Liu Qiaoya

Postcode: 273100

Telephone: +86-537-4498623

Email: qfsswj@126.com


No. 168 Liaocheng Hide Glue Industrial Park Project

I. Project name

Liaocheng Hide Glue Industrial Park Project

II. Brief introduction of project unit

Hide Glue Industrial Park is located in the area in the south of Shuguang Street, west of Xiangjiang Road, east of Gongye Street and south of E’jiao Street, Dong’e County Economic Development Area, and has total building area of 1,600 mu. It mainly has various enterprises such as Shandong Dong’e Hide Glue Co., Ltd., Shandong Dong’e Guojiaotang Hide Glue Drug Co., Ltd. and Dong’e Bainiantang Hide Glue Sales Co., Ltd. 10 Million Hide Glue Biologic Industrial Park project, invested by Hong Kong China Resources Group is under construction. The project mainly produces various products such as hide glue health food, Chinese patent drug, biologic agent, medical instrument and medicinal accessory material.

III. Project contents and construction capacity

The project bases on traditional hide glue brand advantage, introduces hide glue series product and health product enterprises, extends industrial chain, improves industrial added value, and makes great efforts in comprehensive, high grade and large production base of various products such as Chinese patent drug, health food, health care cosmetic and donkey meat.

IV. Project construction conditions

Dong’e is “town of hide glue”, “good place for health maintenance”, glue and health care production enterprises are famous in China, its hide glue output and exporting quantity take over 75% and 90% of the whole country respectively, and Dong’e becomes new nutrition and health product industrial base.

V. Total project investment

USD 350 million

VI. Analysis and prediction of market and economic benefits

After project reaches its design capacity, it can realize annual sales income of USD 1.2 billion.

VII. Cooperation form

Joint venture, cooperative operation.

VIII. Contact information

Address: No. 116, Wenhua Street, Dong’e County, Shandong Province

Contact: Chen Shuguang

Postcode: 252201

Telephone: +86-635-3289072

Email: desw0635@163.com


No. 169  Liaocheng Bioactive Polypeptide Agent Production Project

I. Project name

    Liaocheng Bioactive Polypeptide Agent Production Project

II. Brief introduction of project unit

Shandong Shenxian Jinxing Livestock and Poultry Co., Ltd, established in 2003, is located in Liaocheng Luxi Economic Development Area. The company integrates breeding poultry, incubation, forage, breeding and processing, has main products such as plain chicken, eviscerated chicken, conditioning chicken, cooked food and string type food, sells its products to large and middle cities such as Guangzhou, Shenzhen, Shanghai, Beijing and Tianjin, and realizes annual sales volume of over RMB 500 million.

III. Project contents and construction capacity

The project introduces production line to realize 600 ton/year bioactive polypeptide agent.

IV. Project construction conditions

Bioactive polypeptide agent is mainly used for curing and preventing various poultry diseases. Shenxian County is large animal husbandry county and town of China small meat chicken, and has 600 million piece/year meat chicken; surrounding farming animal husbandry develops quickly. Demand on bioactive polypeptide agent is large, and market prospect is wide.

V. Total project investment

USD 25 million

VI. Analysis and prediction of market and economic benefits

After project reaches its design capacity, it can realize annual sales income of RMB 240 million, profit and tax of RMB 72 million, including profit of RMB 57 million.

VII. Cooperation form

Joint venture, cooperative operation.

VIII. Contact information

Address: East end, Liaocheng Luxi Economic Development Area.

Contact: Wang Zhijie

Postcode: 252400

Telephone: +86-13906357436

Email: mfjyxk66@163.com


No. 170 Qingdao Life Technology Industry Investment Promotion Project

I. Project name

Qingdao Life Technology Industry Investment Promotion Project

II. Brief introduction of project unit

Planning area of life technology industry gathering area is between Huashan Third Road in the east, Qingyin Expressway and Weiqing Expressway in the west, 1,400 m away form Yingpu Road in the north and Qingwei Road in the south, and has about 24 km2. Life technology core area is between Huashan Third Road in the east, east of Huangjiabu South Village in the west, Yingpu Road in the north and Qingwei Expressway and Kongquehe Third Road in the north and Qingwei Road in the south, has about 3.5 km2, gathers large projects with high technical content and strong driving power and foreign and domestic enterprises with strong influence in life technology industry, and actively attracts relevant and auxiliary high grade upper and lower stream industries to stay.

III. Project contents and construction capacity

The project will be built into new high grade industry gathering area, which uses biologic and medical engineering products such as high-tech medical equipment and medical material as basis, and includes biologic and medical relevant industries such as biologic technology drug and diagnosis agent.

IV. Project construction conditions

The first stage of Toray project - haemodialysis machine entered trial production, and the second stage - artificial kidney project built factory building of 11,000 m2, and put into operation at the end of 2012.

V. Total project investment

USD 500 million

VI. Analysis and prediction of market and economic benefits

Staying projects in life technology industry gathering area include Japan Toray haemodialysis machine project, microbial oil and baby milk formula project, Switzerland helico-centrifugal pump project, Japan hydrogen essence water equipment project, etc.

VII. Cooperation form

Solely foreign funded, joint venture.

VIII. Contact information

Address: Jimo City, Shandong Province

Contact: Zhou Shaoxia

Postcode: 266000

Telephone: +86-532-88556506

Email: jimoswj@126.com


No. 171 Weihai Marine Bioactive Extract, American Ginseng Extract and Pectin Production Project

I. Project name

Weihai Marine Bioactive Extract, American Ginseng Extract and Pectin Production Project

II. Brief introduction of project unit

Weihai Huayang Drug Co., Ltd., established in 1992, is modern pharmaceutical enterprise that integrates scientific research, production and marketing. It has plant area of 35,000 m2, building area of 15,000 m2, registered capital of RMB 56.4 million and total assets of RMB 115 million. The company obtained GMP authentication certificate in May 2004, and passed re-authentication in March 2009. At present, it has agent types with 5 forms and 19 approval numbers, i.e., tablet, hard capsule, granule, ointment and oral liquid.

III. Project contents and construction capacity

1. It introduces drug and food high production technologies, including but not limit to marine bioactive extract production, pectin production, American ginseng extract, etc. 2. It wants to make market cooperate with foreign and domestic specialized factories, and to expand new international and domestic markets by existing production technology and equipment.

IV. Project construction conditions

Weihai Huayang Drug Co., Ltd., has 19 agent types with approval numbers and GMP authentication, and owns advanced production equipments. Wendeng City is abundant in various marine products, is important production base of Chinese apple and American ginseng, and provides the most favorable raw material and production conditions for project implementation.

V. Total project investment

USD 30 million

VI. Analysis and prediction of market and economic benefits

After the project is put into production completely, it can realize annual new sales income of RMB 300 million and profit of RMB 50 million.

VII. Cooperation form

Joint venture, technical cooperative operation, trade cooperative operation.

VIII. Contact information

Address: Wendeng Commercial Bureau

Contact: Li Zongwen

Postcode: 264400

Telephone: +86-631-8456416

Email: wdwzgl@163.com


No. 172 Zaozhuang Chiral Agent Construction Project

I. Project name

Zaozhuang Chiral Agent Construction Project

II. Brief introduction of project unit

Zaozhuang Baike Drug Co., Ltd, established in 1976, is pharmaceutical enterprise with long history in Zaozhuang City, has factory area of 105 mu, and owns workshops and office area of 86,000 m2. Production range of the company includes agent forms such as small volume injection solution, powder injection (cephalosporin) and freeze drying powder injection, and it has 45 drugs approved by State State Food and Drug Administration.

III. Project contents and construction capacity

The project has factory area of 105 mu, workshops and office area of 86,000 m2, and is planning to build 9 finished drug GMP production lines within international topping level, including 1 eye medicine production line (eye drop), 2 Respiratory system drug production lines (tablet; aerosol), 2 anti-cancer drug production lines (powder injection or freeze drying powder; tablet, 1 nerve tye drug production line (capsule), 1 cardiovascular drug and gastrointestinal drug production line (tablet) and 2 small volume injection agent production lines (final sterilization; non-final sterilization). 2 small volume injection agent production lines are to be finished in the middle of 2014, and passes new version GMP authentication.

IV. Project construction conditions

The project is handling preliminary procedures such as establishment and environmental protection, and is now building factory building.

V. Total project investment

USD 98.82 million

VI. Analysis and prediction of market and economic benefits

After the project is put into production completely, it can realize annual new sales income of RMB 2 billion and profit of RMB 450 million.

VII. Cooperation form

Joint venture, cooperative operation.

VIII. Contact information

Address: North side, Shengong Road, Zaozhuang High-tech Area

Contact: Chen Fanjie

Postcode: 277800

Telephone: +86-632-2989678

Email: fanjie.chen@viwit.com


No.173 Jinan's High and New Technology Development Zone Medicine Valley Industrial Park

I. Project Name

Jinan's High and New Technology Development Zone Medicine Valley Industrial Park

II. Project Overview

At state-level, Jinan High and New Technology Development Zone consists of three zone of central zone (23.3 KM2), Jinan Comprehensive Bonded Zone (5.2 KM2) and Suncun New Zone (104.5 KM2). At present, there are 5000 firms in the zone.

III. Investment Environment

Now, the 33-storey research building for two projects of national comprehensive new drug research platform and national innovation medicine incubation base has finished its civil work. After completion, it will accommodate more than 300 firms and become a core carrier of new drug research and development in Shandong Province.

IV. Cooperation Fields and Direction

Jinan High and New Technology Development Zone is to build a 10,000-mu biotic medicine industrial park in Suncun, to receive big platform achievement industrialization projects. There will be small and medium-sized enterprise expansion zone and big enterprise zone. The small and medium-sized enterprise expansion zone will includes biotic medicine production zone, chemical medicine production zone, traditional Chinese medicine and natural medicine production zone, and medical appliance production zone.

V. Cooperation Form

Joint venture, cooperative operation or solely foreign funded.

VI. Contact Information

Phone: 0086-531-66607160

Email: jn66607160@163.com

Fax: 0531-66607160

Address: Fl. 8 Block D, Long'ao Building, No. 1 Longding Avenue, Lixia District, Jinan, Shandong

Postcode: 250099


No.174 Yantai High and New Technology Development Zone International Biotic Technical Park

I. Project Name

Yantai High and New Technology Development Zone International Biotic Technical Park

II. Project Overview

Yantai High and New Technology Development Zone International Biotic Technical Park is invested jointly by Yantai High and New Technology Development Zone and Shandong Green Leaf Pharmacy Group Co. Ltd. and constructed and operated by Shandong International Biotic Technical Park Development Co. Ltd.. Yantai High and New Technology Development Zone International Biotic Technical Park has been listed in national new drug research and development platform, as an important part of Shandong's important new drug development center. After completion of the project, it will create an innovative biotic technical research and development base first class in China and well known in the world.

III. Investment Environment

The Phase 1 has been initiated to build 5 scientific research buildings and 10 entrepreneur incubation buildings. The initiation building has been put into use and the other buildings completed and put into operation in the later half of 2014.

IV. Cooperation Fields and Direction

Push forward the incubation and industrialization of biotic medicine, marine biotic, biotic agriculture, health medical service and other high-end industries.

V. Cooperation Form

Joint venture, cooperative operation

VI. Contact Information

Contact: Li Zheng

Phone and fax:  0086-535-3800888

Email:  Bioasis@luye.cn


No.175 Yantai Development Zone Biotic Medicine Industrial Park

I. Project Name

Yantai Development Zone Biotic Medicine Industrial Park

II. Project Overview

Established in 1984 as approved by the State Council, Yantai Economic and Technical Development Zone is one of the first batch 14 state-level development zones. In 2012, it realized GDP of RMB 100 billion, local fiscal revenue of RMB 4.66 billion and import/export of USD 27 billion. Yantai Economic and Technical Development Zone has Shandong Simcere Pharmacy, New Age Health Industry and other famous medicine and health product manufacturers.

III. Cooperation Fields and Direction

Biotic medicine and healthy nutritional food industries.

IV. Total Investment

USD 300 million

V. Cooperation Form

Joint venture, solely foreign funded

VI. Contact Information

Contact: Ji Yongqiang

Phone and fax:  0086-535-6396705

Email:  kfq6396697@163.com


No.176 Jiaxiang Economic Development Zone Biotic Industrial Park

I. Project Name

Jiaxiang Economic Development Zone Biotic Industrial Park

II. Project Overview

As a park special for biotic medicine industry, it is oriented to biotic medicine, biotic manufacturing, biological energy, biotic environment protection and biotic service.

III. Investment Environment

The park is located in Jiaxiang Economic Development Zone, with good conditions and convenient communications to receive projects.

IV. Cooperation Fields and Direction

Towards biotic industries, the park introduces high-tech, high added value firms.

V. Cooperation Form

Joint venture, cooperative operation or solely foreign funded.

VI. Contact Information

Phone: 13792392520

Email: jxxlgjjq@163.com

Address: Jiaxiang Economic Development Zone, Jiaxiang County

 

 


No. 17710 billion donkey-hide gelatin biotechnology industry project of Dong-E Economic Development Zone

I. Project name

10 billion donkey-hide gelatin biotechnology industry project of Dong-E Economic Development Zone

II. Briefings of project unit

    Dong-E is a national important production base of donkey-hide gelatin and donkey-hide gelatin products. Shandong DEEJ Co., Ltd. is a national leading enterprise with output and export volume of donkey-hide gelatin respectively accounting for more than 75% and 90% of total amount. Currently, Dong-E has already became a newly emerging dietary supplement industrial base and health maintenance, leisure and tourism destination.

III. Project contents and construction capacity

    Donkey-hide gelatin biotechnology industry project is located in Dong-E Economic Development Zone and covers an area of more than 1,000 mu with construction area of 500,000 m2. The project is divided into two phases. Phase I mainly focuses the construction of workshop, logistics warehouse and other facilities with construction area of 167,000 m2and purchases advanced production facilities and laboratory apparatus with annual output of 150,000 tons of donkey-hide gelatin and donkey-hide gelatin products. Phase II focuses on the construction of donkey industry research institute, national gelatins traditional Chinese medicine engineering research center, biotechnology research laboratory and 5A sight-seeing tour zone to promote R&D and production of new genetic engineering drugs, drive on industrialization and internationalization progress of biopharmaceutical industry and create a large national comprehensive drug R&D technical platform. After completion, Dong-E will form four industrial bases of donkey-hide gelatin and traditional Chinese medicine, aesthetic health care, ass meat processing and biopharmaceutical industries and a national 5A industrial tourism area. 

IV. Total investment

    USD 1644.437 million 

V. Market forecast and analysis

    After being put into operation, the project is planning to realize annual sales revenue of 14.5 billion Yuan and profits of 2.35 billion Yuan.

VI. Way of cooperation

    Joint venture and cooperative operation

VII. Contact information

    Contact person: Cui Qingshen 0086-635-3261817

    Telephone& Fax: 0086-635-3261817  E-mail: lcjmwz@163.com


No. 178 Biological medicine industrialization base construction project of Shandong Shennuoji Pharmaceutical Co., Ltd.

I. Project name

    Biological medicine industrialization base construction project of Shandong Shennuoji Pharmaceutical Co., Ltd.

II. Briefings of project unit

    The company was established on January 10, 2012 with registered capital of 10 million Yuan. The company is established by Beijing Shenaoji Pharmaceutical Co., Ltd. and is mainly engaged in industrial production of Class I original new drugs. Currently, the company is promoting industrialization of Icaritin crude drug and their products belong to national Class I new anti-tumor drugs which have significant effect on restraining mammary cancer, endometrial carcinoma and liver cancer cells. Meanwhile, the company is also taking an active participate in semi-work production and industrialization of new anti-tumor chemical synthesis drugs, diagnostic reagent, monoclonal antibody and other national Class I new drugs.

III. Project contents and construction capacity

    The project mainly constructs extraction workshop, R&D and semi-work production workshop, power plant, warehouse and other facilities with construction area of 56,570 m2 and purchases 276 sets of equipments, such as stainless steel retort, reaction kettle and auto-control system.

IV. Project construction conditions

    The project is located in the south of Huihe Avenue, Laicheng Industrial Park, Laiwu City and in the east of South Zhuhai Road. Necessary formalities are completely prepared at earlier stage of project and it has already matched construction conditions.

V. Total investment

    USD 280 million

VI. Market forecast and analysis

    After being put into full operation, the project is planning to annually produce 1,500 kg Icaritin crude drugs, newly increase sales revenue of 3 billion Yuan and realize profit of 800 million Yuan.

VII. Way of cooperation

    Joint venture and cooperative operation

VIII. Contact information

    Contact person: Wei Zhenyu

    Telephone & Fax: 0086-13963405357

    E-mail: weizhenyu@163.com